NYSEARCA:XBI SPDR S&P Biotech ETF (XBI) Price, Holdings, & News $93.23 +1.52 (+1.66%) (As of 07/8/2024 ET) Add Compare Share Share Today's Range$92.44▼$93.6850-Day Range$84.62▼$94.1252-Week Range$63.80▼$103.52Volume9.00 million shsAverage Volume10.57 million shsMarket Capitalization$7.11 billionAssets Under Management$6.98 billionDividend Yield0.02%Net Expense Ratio0.35% Stock AnalysisStock AnalysisChartDividendHeadlinesHoldingsOwnershipRatingsStock AnalysisChartDividendHeadlinesHoldingsOwnershipRatings Get SPDR S&P Biotech ETF alerts: Email Address About SPDR S&P Biotech ETF (NYSEARCA:XBI)SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor.Read More XBI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XBI ETF News HeadlinesMay 24, 2024 | investorplace.comWhy the Rest of 2024 Could Be Good for Investing in Biotech StocksMay 14, 2024 | msn.comEvercore says biotech ‘winter is finally thawing’July 9, 2024 | Weiss Ratings (Ad)The only way to play the AI boom?A new AI profit window is opening. But I believe if you want to take advantage of this next wave of AI … You have to do something very few people will have the courage to do.May 12, 2024 | msn.comCantor picks 14 undervalued biotech stocks worth a second lookApril 30, 2024 | msn.comStock Market Crash Warning: Don’t Get Caught Holding These 3 Biotech StocksApril 28, 2024 | nasdaq.comXBI June 7th Options Begin TradingApril 21, 2024 | seekingalpha.comSome Bubbles Are Starting To PopApril 20, 2024 | seekingalpha.comNovartis Looks To Get Back On Track With Q1 EarningsJuly 9, 2024 | Weiss Ratings (Ad)The only way to play the AI boom?A new AI profit window is opening. But I believe if you want to take advantage of this next wave of AI … You have to do something very few people will have the courage to do.March 28, 2024 | msn.com2 Top Biotech Buyout CandidatesSee More Headlines Receive XBI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SPDR S&P Biotech ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address Fund Details IssuerSSgA Fund NameSPDR S&P Biotech ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:XBI Inception Date1/31/2006 Fund ManagerMichael Feehily, Karl Schneider, Raymond Donofrio Webwww.spdrs.com Phone+1-866-7872257Fund Focus Asset ClassEquity BenchmarkS&P Biotech Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings143 Fund Statistics Assets Under Management$6.98 billion Average Daily Volume$7.62 million Discount/Premium-0.07% Administrator, Advisor and Custodian AdministratorSSgA Funds Management, Inc. AdvisorSSgA Funds Management, Inc. CustodianState Street Bank and Trust Company DistributorState Street Global Advisors Funds Distributors, LLC Transfer AgentState Street Bank and Trust Company TrusteeN/A Lead Market MakerVirtu Financial Options OptionableOptionable Options Volume38,562 Put Options8,577 Call Options29,985 Short Interest59,610,000 shs Miscellaneous Outstanding Shares76,220,000Beta1.11 Creation Unit50,000 Creation Fee$250.00 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Ad Theo TradeReplace Lost Dividend Income with This…Introducing Ultima Trades, a unique strategy designed by Don Kaufman. Ultima Trades capitalize on market inflection points to deliver substantial returns, providing a powerful alternative to traditional dividends. Imagine securing gains like 21%, 30%, or even 305% in just hours or days, ensuring a reliable source of income.Click here to download the eBook and start transforming your income today. SPDR S&P Biotech ETF ExpensesTypeXBIHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.35%0.56%0.54%0.51%0.51%Other Expenses0.00%0.33%0.50%0.59%0.54%Total Expense0.35%0.70%0.70%0.74%0.71%Fee Waiver0.00%-0.45%-0.55%-0.69%-0.59%Net Expense0.35%0.61%0.60%0.58%0.59% SPDR S&P Biotech ETF (XBI) Holdings & ExposureTop 10 XBI HoldingsSarepta Therapeutics(NASDAQ:SRPT)Holding Weight: 3.28%Alnylam Pharmaceuticals(NASDAQ:ALNY)Holding Weight: 2.99%United Therapeutics(NASDAQ:UTHR)Holding Weight: 2.97%Amgen(NASDAQ:AMGN)Holding Weight: 2.85%Exact Sciences(NASDAQ:EXAS)Holding Weight: 2.83%Gilead Sciences(NASDAQ:GILD)Holding Weight: 2.81%Natera(NASDAQ:NTRA)Holding Weight: 2.72%Regeneron Pharmaceuticals(NASDAQ:REGN)Holding Weight: 2.72%Vertex Pharmaceuticals(NASDAQ:VRTX)Holding Weight: 2.69%AbbVie(NYSE:ABBV)Holding Weight: 2.67%XBI Sector ExposureXBI Industry ExposureFull Holdings Details Key ExecutivesJames E. Ross (Age 52)President, Trustee Peter A. Ambrosini (Age 69)Chief Compliance Officer Michael P. Riley (Age 44)Vice President Gary L. French (Age 64)Treasurer John W. Clark (Age 46)Assistant Treasurer Matthew W. Flaherty (Age 42)Assistant Treasurer Chad C. Hallett (Age 47)Assistant Treasurer of Street tracks series trust Mary Moran Zeven (Age 52)Secretary Scott M. Zoltowski (Age 44)Assistant Secretary Dave KellyIndependent TrusteeMore ExecutivesSimilar ETFsiShares Biotechnology ETFNASDAQ:IBBiShares U.S. Medical Devices ETFNYSEARCA:IHIiShares Global Healthcare ETFNYSEARCA:IXJiShares U.S. Healthcare ETFNYSEARCA:IYHFidelity MSCI Health Care Index ETFNYSEARCA:FHLCInstitutional OwnershipCollective Family Office LLCBought 2,558 shares on 7/5/2024Ownership: 0.003%Transcend Capital Advisors LLCBought 3,774 shares on 7/2/2024Ownership: 0.071%Bank of New HampshireSold 135 shares on 7/1/2024Ownership: 0.001%Verity Asset Management Inc.Bought 777 shares on 5/28/2024Ownership: 0.024%Cetera Advisors LLCBought 40,184 shares on 5/24/2024Ownership: 0.128%View All Institutional Transactions XBI ETF - Frequently Asked Questions How have XBI shares performed this year? SPDR S&P Biotech ETF's stock was trading at $89.29 at the start of the year. Since then, XBI shares have increased by 4.4% and is now trading at $93.23. View the best growth stocks for 2024 here. Who are SPDR S&P Biotech ETF's major shareholders? Top institutional investors of SPDR S&P Biotech ETF include Transcend Capital Advisors LLC (0.07%), Collective Family Office LLC and Bank of New Hampshire. How do I buy shares of SPDR S&P Biotech ETF? Shares of XBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of SPDR S&P Biotech ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that SPDR S&P Biotech ETF investors own include Intel (INTC), NVIDIA (NVDA), Pfizer (PFE), Gilead Sciences (GILD), iShares Biotechnology ETF (IBB), Walt Disney (DIS) and Micron Technology (MU). This page (NYSEARCA:XBI) was last updated on 7/9/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredGrab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house...Wealthpin Pro | SponsoredUnexpected twist to Trump’s trialUnexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | SponsoredTop Hedge Funds Reveal A.I. Moonshot CoinsThe manager of top crypto hedge fund Pantera recently said every crypto company will soon be an artificial int...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SPDR S&P Biotech ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share SPDR S&P Biotech ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
